肿瘤细胞治疗研究
英文原题：Outcomes of allogeneic hematopoietic stem cell transplantation in R/R DLBCL patients with failure of CAR-T therapy.
10例患者中，男性5例，女性5例，中位年龄43.5（27-52）岁。
2017年10月至2022年6月，我们回顾性报告了CAR-T治疗失败后接受allo-HSCT的R/R DLBCL患者的结局。10例患者中，男性5例，女性5例，中位年龄43.5（27-52）岁。所有患者均诊断为难治/复发性弥漫性大B细胞淋巴瘤。从CAR-T治疗至移植的中位时间为84.5（31-370）天。中位随访时间为21（3-69）个月。随访期间，5/10例患者达到CR，1/10例患者达到PR。客观缓解率（ORR）为60%。1年总生存（OS）率和无进展生存（PFS）率分别为70%和40%。分析时，6例患者仍存活。随访期间，4例患者死亡，死因为疾病复发和进展（2例）、急性肾衰竭（1例）、严重肺部感染（1例）。非复发死亡率为20.0%。
From October 2017 to June 2022, we retrospectively report outcomes of R/R DLBCL patients with failure of CAR-T therapy, then receiving allo-HSCT. Among 10 patients, 5 were males and 5 females, with a median age of 43.5 (27-52) years. All patients were diagnosed refractory/relapsed diffuse large B cell lymphoma. The median time from CAR-T treatment to transplantation was 84.5 (31-370) days. The median follow-up was 21 (3-69) months. 5/10 patients attained CR and 1/10 patient attained PR during the follow up. The objective response rate (ORR) was 60%. The 1-year overall survival (OS) and progression-free survival (PFS) were 70% and 40%, respectively. At the time of the analysis, 6 patients were still living. During the follow up, four patients have died and the causes were disease relapses and progressions (2 patients), acute renal failure (1 patient), severe pulmonary infection (1 patient). Non-relapse was 20.0%.
MEMBER ACCOUNT
登录成功会直接打开下一页。
